Stimate®

Before the initial therapeutic administration of Stimate Nasal Spray, the physician should establish that the patient shows an appropriate change in the coagulation profile following a test dose of intranasal administration of Stimate Nasal Spray.

Hemophilia A

- Stimate Nasal Spray is indicated for patients with hemophilia A with Factor VIII coagulant activity levels greater than 5%.
- Desmopressin acetate will also stop bleeding in patients with hemophilia A with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.

Desmopressin acetate is not indicated for the treatment of hemophilia A with Factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have Factor VIII antibodies.

Von Willebrands Disease (Type I)

- Stimate Nasal Spray is indicated for patients with mild to moderate classic von Willebrands disease (Type I) with Factor VIII levels greater than 5%.
- Desmopressin acetate will also stop bleeding in mild to moderate von Willebrands disease patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas, mucosal bleeding or menorrhagia.

Bleeding time and Factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked after initial administration of Stimate Nasal Spray to ensure that adequate levels have been achieved.

Stimate Nasal Spray is not indicated for the treatment of severe classic von Willebrand disease (Type I) and when there is evidence of an abnormal molecular form of Factor VIII antigen.

For indications, dosing and other information, please refer to the prescribing information.

Stimate® ‐ CSL Behring

Size:
1.5 mg, 1 mL
NDC #:
00053-6871-00
Download:
PI